RMD— AI Stock Forecast & Price Targets
Published 6/14/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live RMD price forecast →
ResMed offers a high-quality medical device franchise trading at a meaningful discount to its own history after a ~23% YoY decline driven by GLP-1 disruption fears, with shares near 52-week lows ($194.78 vs. $293.81 high) and forward P/E of ~16x against ~12% EPS growth and 25% ROE. Fundamentals remain robust (62% gross margin, 35% operating margin, $1.45B FCF, near-net-cash balance sheet), and the Kronos forecast plus a bullish sell-side target ($280.18) suggest a constructive near-to-mid-term setup, though the long-term GLP-1 secular question is unresolved.
1-4 weeks: Tactical long bias. With price at $194.78, RSI 43, and the Kronos 1h/4h models pointing to $228-$258, a starter position with a stop on a weekly close below $180 (52W low) makes sense. Size at 1/3 of intended position to allow adds on either a reclaim of $210 (confirmation) or a flush to $182-185 (capitulation). Invalidation: daily close below $180 on volume.
1-6 months: Constructive. Catalysts include the Apr-30 earnings print, continued evidence that GLP-1 attrition is bounded (already echoed in two 6/11 articles), and incremental Noctrix/RLS data. Expected return range +15% to +30% to $225-$255 if margins hold above 34% and revenue growth stays double-digit. What would change my mind: a quarterly revenue miss, gross margin slip below 60%, or a guide-down explicitly citing GLP-1 patient drop-off.
1-3 years: Base case is a quality compounder re-rate as the market confirms sleep apnea TAM is structurally intact despite GLP-1s, supported by 12% LT EPS growth, 25% ROE, and software/EHR optionality (Brightree, MatrixCare, MEDIFOX DAN). The Kronos weekly forecast hints at a rally-and-fade pattern, which is a real warning that this could remain a range-bound name. Biggest structural risk: GLP-1 (and successor obesity drugs) materially shrinking the diagnosed OSA pool over 5-10 years, compressing both growth and the multiple.
Revenue growth is steady and reaccelerating modestly: quarterly revenue stepped from $1.348B (Jun-25) to $1.336B → $1.423B → $1.431B (Mar-26), with Sales Y/Y TTM of 10.3% and EPS Q/Q of 10.4%. Margins are expanding — gross margin moved from 60.8% to 62.2% over four quarters and operating margin sits at ~34.9%, with net margin near 27.9%. Profitability metrics are top-tier (ROE 25.2%, ROIC 21.6%, ROA 18.6%). The balance sheet is fortress-like: $1.66B cash vs. $843M debt (net cash), current ratio 3.0, Debt/Eq 0.13, working capital of $2.71B. Cash generation is excellent — TTM FCF $1.45B (P/FCF ~16x), and the latest quarter delivered $514M FCF on $554M operating cash. Capital allocation looks disciplined: capex is light (~$40M/qtr), dividend payout is modest at 22.3% (1.23% yield) with 3Y dividend growth of 8%, leaving ample room for the Noctrix-style bolt-on M&A management just executed. Nothing in the financials looks broken; the bear case is entirely about future demand elasticity, not current execution.
Across the daily and weekly views, RMD is in a clear downtrend — price is -20.3% vs. its 200-day SMA, -7.2% vs. 50-day, -1.8% vs. 20-day, with Perf YTD -19.1% and Perf Year -22.8%, sitting ~33.7% below the 52-week high of $293.81 and just ~8% above the 52-week low of $180.27. RSI(14) at 43.3 is neutral-to-weak, not yet oversold. The Kronos models diverge by timeframe in a notable way: the 1h and 4h forecasts are constructively higher (targets $228.29 and $258.18 — implying ~17-32% upside near-term), while the 1d forecast band is more muted ($235 area with a wide dispersion), and the 1wk forecast shows a rally toward ~$250 followed by a rollover back to ~$197 by 2028 — consistent with a tactical bounce inside a still-broken secondary trend. Key support is the May/June low cluster around $180-185 (also the 52W low); resistance steps are $210 (March breakdown), $230 (June 2025 pivot), then $260. A weekly close back above $210 would be the first real trend-repair signal.
Newsflow is incrementally constructive but does not resolve the central debate. Two bullish-leaning items from 6/11 (Insider Monkey/Yahoo write-ups citing a Reddit bull thesis at $196.94, and Seeking Alpha's 'GLP-1 Threats Are Overstated' piece) directly push back on the dominant bear narrative, arguing share loss will be partial and remaining patients more profitable. The 6/5 Noctrix Health acquisition is a small but strategically interesting expansion into Restless Legs Syndrome via non-pharmacologic wearables — a credible adjacency that diversifies away from pure sleep apnea. Zacks/Yahoo (6/9) frame it as a 'retain' with acknowledged macro and competitive pressures. The William Blair conference appearance is a presence item, not a catalyst.
- Noctrix Health acquisition (closed 6/1/2026) opens the Restless Legs Syndrome market via non-pharmacologic wearables — first material diversification beyond sleep apnea
- Residential Care Software segment (Brightree, MatrixCare, HEALTHCAREfirst, MEDIFOX DAN) provides recurring SaaS revenue insulated from GLP-1 device-demand risk
- Gross margin expansion runway: 60.8% → 62.2% over four quarters signals mix shift and pricing power; further mask innovation cycle cited in 6/9 Zacks note
- AirView/myAir connected-care platform monetizes installed base and supports compliance-linked reimbursement
- Net cash position ($817M net) plus $1.45B annual FCF supports continued tuck-in M&A at depressed valuations
- GLP-1 secular threat remains the dominant overhang — Perf Year -22.8% and Perf YTD -19.1% reflect ongoing market skepticism
- Short interest is elevated at 8.27% of float / 9.15 days to cover, signaling persistent bearish positioning
- Kronos weekly forecast projects a rollover back toward $197 by 2028 — model itself flags limited LT upside
- Technical setup is still broken: -20% below 200-DMA, no confirmed reversal, RSI not yet oversold
- Valuation is reasonable but not deep-value: forward P/E ~16x, PEG 1.32, EV/EBITDA 12.5x — limited margin of safety if growth decelerates
- Insider transactions -3.02% (net selling) provides no internal vote of confidence
- Competitive pressure noted in 6/9 Zacks article alongside Philips Respironics recovery risk
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord